Risk of senescence, polypharmacy, and their outcomes in elderly cardiovascular disease patients
Advances in Pharmacology, Academic Press , ss.351-392, 2025
- Yayın Türü: Kitapta Bölüm / Araştırma Kitabı
- Basım Tarihi: 2025
- Doi Numarası: 10.1016/bs.apha.2025.02.011
- Yayınevi: Academic Press
- Sayfa Sayıları: ss.351-392
- Anahtar Kelimeler: Aging, Cardiac surgery, Drug interactions, Elderly, Polypharmacy, Senescence, Senotherapeutic drugs
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Cardiovascular diseases (CVDs) are closely associated with a chronic inflammatory condition known as senescence and present a considerable challenge when managed alongside age-associated comorbidities. Due to the coexistence of three main predisposing factors (advanced age, multiple morbidity, and polypharmacotherapy), elderly patients with CVDs are prone to the occurrence of drug interactions and adverse effects of incorrect drug combinations. Polypharmacy, routine cardiovascular medications, and age-related pharmacokinetic alterations are the major challenges in cardiovascular practice. Polypharmacy might impair the post-surgical recovery process due to ADRs and side effects. Ironically, patients with CVDs may also require conventional senotherapeutic drugs such as cardiac glycosides, statins, aspirin, ACE inhibitors, and angiotensin receptor blockers for their daily routine. Considering medical necessities, polypharmacy, and drug safety of the elderly population, the management of elderly cases presents a serious challenge. We aim to present the cardiometabolic impacts of polypharmacy management in elderly patients and to design optimal senotherapeutic strategies and drug management strategies in cardiac surgical practice.